Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Verwendung von omnidirektionaler virtueller Realität und Laufbandtraining bei chronischem Schlaganfall (PROVE)

2. Oktober 2026 aktualisiert von: Adria Quigley, Nova Scotia Health Authority

PROVE-VR: Eine randomisierte Pilotstudie mit omnidirektionaler virtueller Realität und Laufbandtraining für Überlebende eines chronischen Schlaganfalls

The primary objective of this pilot randomized controlled trial (RCT) is to test the feasibility (consent rate, retention rate, participant burden, adherence, technical issues, safety) and usability (system usability scale, SUS) of Omnidirectional treadmill Virtual Reality training (omni-VR) among chronic stroke survivors. Our secondary objective is to (1) estimate the extent to which cognition, brain activation during a dual task activity, walking ability, and dynamic balance change after 3 months of training among intervention participants (omni-VR) and traditional exercise controls, and (2) estimate the extent to which health-related quality of life and motivation co-evolve with our secondary outcomes.

Researchers will compare the intervention group and control group to evaluate the impact of omni-VR on cognition and physical function among stroke survivors.

Participants will:

  • undergo a 45-minute training session 3 times per week for 12 weeks
  • intervention group: omni-VR
  • control group: traditional exercise program (strengthening and walking activities)

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Mounting data indicates that cognition plays a role in complex walking and balance. However, conventional intervention methods lack a sufficient incentive to encourage participants to adhere to the treatment. Further, it is difficult to provide a substantial amount of treatment to induce cortical reorganization.

Virtual reality or VR (a computer-generated simulation of 3-dimensional virtual environments that reacts in real time to the user's actions) has been introduced to neurorehabilitation to promote improvements in walking ability, balance, and cognition. It has also been demonstrated to be effective in improving motivation among stroke survivors and augmenting neuroplasticity.

Omnidirectional treadmill technology can be integrated with VR to allow for fully immersive rehabilitation. This novel and innovative technology mimics real-world environments and maximizes challenging cognitive and physical dual-tasking and balance activities while maintaining patient safety. However, no randomized trials have evaluated the impact of omnidirectional treadmill VR (Omni-VR) on cognitive and physical function among stroke survivors.

Therefore, our study aims to test the feasibility and usability of the Omni-VR. This pilot randomized control trial will also be the first study to test the feasibility and effect of a fully-immersive active omni-VR system among chronic stroke survivors

Studientyp

Interventionell

Einschreibung (Geschätzt)

30

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

  • Kanada
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 4K4
        • Rekrutierung
        • Nova Scotia Rehabilitation & Arthritis Centre
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria

  • Age ≥ 18
  • Stroke ≥ 6 months ago (confirmed with chart review)
  • Living within 50 km of Halifax, Nova Scotia
  • Functional Ambulation Category of 3 or greater on a scale of 0-5, to ensure the participant is able to walk with supervision or independently. This criterion was selected to ensure participants could safely participate in the intervention.
  • Ability to participate in low-moderate intensity aerobic or strengthening exercise for ≥ 15 minutes to ensure participants can tolerate intervention sessions of 30-45 minutes, with activity breaks, in keeping with previous stroke rehabilitation studies.
  • No uncorrected visual deficits or spatial neglect
  • No cardiovascular, orthopedic, or neurological diseases other than stroke impacting walking or balance
  • Can follow simple instructions
  • Score of < 27 on the adapted Motion Sickness Susceptibility Scale-Short based on established normative values indicating more than moderate susceptibility to motion sickness.

Exclusion Criteria:

  • Unstable serious medical condition
  • Resting blood pressure >180/100mmHg
  • History of abnormal untreated heart rhythm
  • Pregnancy
  • Condition limiting ability to complete or tolerate the exercises without major program modifications (e.g., chronic low back pain)
  • Serious comorbid condition that would affect participation in the intervention (e.g., active cancer, severe heart disease)
  • Severe loss of hearing or speech that would preclude VR use
  • Participant weight more than 264 lbs (weight limit for Virtualizer Elite 2 treadmill)
  • Participating in another formal lower limb exercise program > 1 day per week
  • History of QT prolongation or using potential QT prolonging drugs

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Omni-VR group

20 participants will undergo 45-minute training sessions 3 times per week for 12 weeks using omnidirectional virtual reality and treadmill training.
Gerät: Omnidirectional Virtual Reality and Treadmill Training

Omni-VR forest scenario developed by our team involving real-life dual task walking and dynamic balance activities (ie. stepping over obstacles, and managing distractions) will be used for treatment group.
Aktiver Komparator: Control group

10 participants will undergo 45-minute traditional physiotherapy training sessions including lower limb strengthening and unidirectional treadmill training 3 times per week for 12 weeks.
Verhalten: Traditional Exercise

A traditional exercise program including strengthening and unidirectional treadmill activities for the same duration will be completed in control group.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Consent rate
Zeitfenster: Baseline

Consent rate is the percentage of eligible individuals who participate. The investigators expect a consent rate of at least 40%.
Baseline
Retention rate
Zeitfenster: 12 weeks (study completion)

Retention rate is the percentage of participants who complete the 12-week intervention. The investigators expect a retention rate of 80% for the intervention group.
12 weeks (study completion)
Usability of the Omnidirectional Treadmill and Virtual Reality Game
Zeitfenster: 12 weeks (study completion)

Usability will be assessed by System Usability Scale (SUS) out of 100 points. The investigators expect a SUS score of 71 or higher among all participants.
12 weeks (study completion)
Participant burden
Zeitfenster: Baseline and 12 weeks (study completion)

Participant burden will be measured by the percentage of participants finishing assessments in 100 minutes or less. The investigators anticipate at least 85% of participants completing assessments within the time limit.
Baseline and 12 weeks (study completion)
Adherence
Zeitfenster: 12 weeks (study completion)

Adherence will be measured by the exercise session attendance. The investigators expect the treatment group to attend 70% or more of the sessions.
12 weeks (study completion)
Equipment downtime
Zeitfenster: 12 weeks (study completion)

The investigators will record any treadmill downtime due to VR technical issues. The targets are zero significant downtime in 85% of sessions.
12 weeks (study completion)
Equipment safety
Zeitfenster: 12 weeks (study completion)

The investigators will record any serious adverse events related to the study. The target is no serious adverse events related to the study
12 weeks (study completion)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Cognitive function
Zeitfenster: Baseline and 12 weeks (study completion)

The investigators will use the Computerized MoCA [Montreal Cognitive Assessment] Duo to evaluate participants' cognitive function.
Baseline and 12 weeks (study completion)
Executive Function
Zeitfenster: Baseline and 12 weeks (study completion)

The investigators will use the Dimensional Change Card Sort to evaluate participants' executive function.
Baseline and 12 weeks (study completion)
Working memory
Zeitfenster: Baseline and 12 weeks (study completion)

The investigators will use the List Sorting Working Memory Test to evaluate participants' working memory.
Baseline and 12 weeks (study completion)
Brain activation in prefrontal and premotor cortices
Zeitfenster: Baseline and 12 weeks (study completion)

Brain activation using fNIRS [Functional near-infrared spectroscopy] in the prefrontal and premotor regions of interest during a single task (steady-state omnidirectional treadmill walking) and two cognitive-physical dual-task activities (simple dual-task: steady-state omnidirectional treadmill walking while repeating the same word and complex dual-task: steady-state omnidirectional treadmill walking while performing a verbal fluency test)
Baseline and 12 weeks (study completion)
Walking Speed
Zeitfenster: Baseline and 12 weeks (study completion)

Walking speed using VIVE trackers on omnidirectional treadmill and overground
Baseline and 12 weeks (study completion)
Step cadence
Zeitfenster: Baseline and 12 weeks (study completion)

The investigators will evaluate step cadence using the VIVE trackers.
Baseline and 12 weeks (study completion)
Step width
Zeitfenster: Baseline and 12 weeks (study completion)

The investigators will evaluate step width using the VIVE trackers.
Baseline and 12 weeks (study completion)
Step length
Zeitfenster: Baseline and 12 weeks (study completion)

The investigators will evaluate step length using the VIVE trackers.
Baseline and 12 weeks (study completion)
Dynamic balance
Zeitfenster: Baseline and 12 weeks (study completion)

The investigators will measure the static sway with feet together using omni-VR system and use MINI-BESTest to measure the dynamic balance.
Baseline and 12 weeks (study completion)

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Motivation of participant
Zeitfenster: 12 weeks (study completion)

The investigators will measure motivation by intrinsic motivation inventory. Higher scores indicate better results.
12 weeks (study completion)
Health-related quality of life of participant
Zeitfenster: Baseline and 12 weeks (study completion)

The investigators will measure health-related quality of life by the Stroke Impact Scale-3.0. Higher scores indicate better results.
Baseline and 12 weeks (study completion)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Nova Scotia Health Authority

Mitarbeiter

Brain Canada

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

28. April 2025

Primärer Abschluss (Geschätzt)

6. August 2027

Studienabschluss (Geschätzt)

6. September 2027

Studienanmeldedaten

Zuerst eingereicht

20. Juni 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. Juli 2024

Zuerst gepostet (Tatsächlich)

10. Juli 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • PROVE_stroke

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren